Literature DB >> 16839322

Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction.

John P Mulhall1, Patricia Guhring2, Marilyn Parker3, Carin Hopps2.   

Abstract

INTRODUCTION: Sildenafil citrate is an effective and well-tolerated oral erectogenic medication. Through phosphodiesterase type 5 (PDE5) inhibition, it induces relaxation in penile smooth muscle, resulting in erection. Due to its mild affinity for other PDE enzymes, it may cause smooth muscle relaxation in a number of other organs. Recent data suggest an association between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS). Anecdotally some patients cite improvement in LUTS while using sildenafil. AIM: This study was conducted to assess the impact of Viagra on LUTS, using the International Prostate Symptom Score (IPSS) questionnaire. MAIN OUTCOME MEASURE: International Index of Erectile Function (IIEF) and IPSS inventories.
METHODS: Men presenting to a sexual dysfunction clinic who were candidates and opted for treatment with sildenafil completed the IIEF and IPSS. Men with the IPSS scores greater than 10 were enrolled and completed the IPSS and IIEF questionnaires at least 3 months after the commencement of sildenafil. Comparisons were made between pre- and posttreatment scores in the IPSS and erectile function (EF) domain of the IIEF.
RESULTS: Forty-eight men were enrolled, with a mean age of 62 +/- 11 years. The mean improvement in the EF domain score was 7 points (P = 0.01). The mean improvement in the IPSS score was 4.6 points (P = 0.013) and in quality of life (QOL) score was 1.4 points (P = 0.025). In total, 60% of men improved their IPSS score, and 35% had at least a 4-point improvement in their score. The mean number of uses of sildenafil per week was 2.0 +/- 0.6. No significant correlation was seen between the degree of the IPSS improvement and baseline IPSS, baseline EF domain score, or magnitude of improvement in EF domain score.
CONCLUSIONS: These data indicate a positive impact of Viagra on men with mild to moderate LUTS. It is presumed, although unproven, that the medication's effect is mediated through bladder neck/prostatic smooth muscle relaxation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16839322     DOI: 10.1111/j.1743-6109.2006.00259.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  31 in total

Review 1.  An overview of prostate diseases and their characteristics specific to Asian men.

Authors:  Shu-Jie Xia; Di Cui; Qi Jiang
Journal:  Asian J Androl       Date:  2012-02-06       Impact factor: 3.285

2.  Clinical efficacy of combination therapy with an alpha blocker and low-dose sildenafil on post-therapy lower urinary tract symptoms after low-dose-rate brachytherapy for prostate cancer.

Authors:  Young Dong Yu; Moon Hyung Kang; Chang Il Choi; Hyun Soo Shin; Jong Jin Oh; Dong Soo Park
Journal:  World J Urol       Date:  2016-02-11       Impact factor: 4.226

Review 3.  Male lower urinary tract symptoms: treatment with a-blockers, 5-a-reductase inhibitors, antimuscarinics, or a combination.

Authors:  Rodney A Appell
Journal:  Curr Urol Rep       Date:  2007-09       Impact factor: 3.092

4.  [Control mechanisms of tonus of smooth muscle of the prostate and their potential significance for pharmacotherapy of benign prostatic syndrome].

Authors:  S Uckert; G Kedia; H Klocker; M Sormes; G Bartsch; U Jonas
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

5.  Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms.

Authors:  Steven A Kaplan; Ricardo R Gonzalez
Journal:  Rev Urol       Date:  2007

Review 6.  The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.

Authors:  Casey Lythgoe; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 7.  The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.

Authors:  Matt T Rosenberg; David Staskin; John Riley; Grannum Sant; Martin Miner
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 8.  Update on the sexual impact of treatment for benign prostatic hyperplasia.

Authors:  John Roger Bell; Eric Laborde
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

9.  Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia.

Authors:  Dean S Elterman; Bilal Chughtai; Richard K Lee; Alexis E Te; Steven A Kaplan
Journal:  Rev Urol       Date:  2012

Review 10.  The role of phosphodiesterases in bladder pathophysiology.

Authors:  Mohammad S Rahnama'i; Stefan Ückert; Ramona Hohnen; Gommert A van Koeveringe
Journal:  Nat Rev Urol       Date:  2013-05-14       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.